Features Pricing Learn Reverse Splits Tracker Shelf & ATM Tracker Warrant Tracker PIPE Deal Tracker Weekly Report FAQ API Sign In →
38 /100
MEDIUM RISK
Score updated Oct 13, 2026

INTS — Intensity Therapeutics, Inc. Dilution Risk Tracker

Track INTS dilution risk with DilutionWatch's stock tracker. DilutionScore™ measures dilution risk across 5 factors — lower scores indicate higher risk of share dilution.

⚠️ Not financial advice. Do your own research before making any investment decisions.

🔔 Track INTS — Get alerts when the score changes →

As of October 13, 2026, Intensity Therapeutics, Inc. (INTS) has a DilutionWatch DilutionScore of 38/100, rated MEDIUM dilution risk. Intensity Therapeutics, Inc. has a market capitalization of $10.81M, 3.26M shares outstanding, 3 institutional holders tracked.

This page includes automatically generated factual summaries from DilutionWatch data. It is not financial advice, not investment research, and not a recommendation. Do your own research. Read the full disclaimer and terms of service.

Score Breakdown

📋 Offering Ability
60
💰 Cash Runway
10
📊 Float Risk
27
⚠️ Warrant Exposure
40
🔄 Convertible Debt
15

Dilution Forecast

☀️
Clear
No significant dilution signals
model est. 0%
No significant dilution signals detected for INTS.
🔔 Track INTS — Get forecast alerts →

Market Data

Market Cap$10.81M
Shares Outstanding3.26M
Float2.47M
Cash$18.48M
DebtN/A
Short InterestN/A

Source-Backed Evidence Depth

This public preview uses stored DilutionWatch fields and linked SEC/market records only. Missing values are not estimated.

FieldCurrent ValueBasis
DilutionScore38/100DilutionWatch score record
Shares Outstanding3.26MVerified float table or market cache
Public Float2.47MVerified float table or market cache
Market Cap$10.81MMarket data cache
Cash Runway24.4 monthsDilutionWatch score inputs
Shelf CapacityNone in current score inputsSEC-derived dilution fields
ATM CapacityNone in current score inputsSEC-derived dilution fields
Outstanding WarrantsNone in current score inputsSEC-derived dilution fields

Recent source-backed SEC insight records available on this page: 7.

Recent SEC source mix: 4 5, XBRL 2.

The page does not infer future share issuance, financing probability, cash needs, management intent, or price impact when source fields are absent.

Institutional Holdings

QoQ: ↓ 97.5% shares (2026Q1 vs prior)
3 institutional holders · 111.0K shares
#1 Corient Private Wealth LLC 100.0K shares
#2 World Investment Advisors 10.0K shares
#3 MORGAN STANLEY 1.0K shares

Institutional holder totals are aggregated from ownership filings and may use a different share basis or reporting date than public float. They are not a reconciliation against tradeable float.

Short Interest

Short Interest38.3K
Days to Cover2.1
% of Float1.6%
FINRA data as of Sep 30, 2026

Recent SEC Activity

xbrl XBRL CONVERTIBLE 2026-03-27
xbrl XBRL WARRANT 2025-03-13
4 INSIDER TRANSACTION 2026-07-20
4 INSIDER TRANSACTION 2026-07-20
4 INSIDER TRANSACTION 2026-07-20
Full SEC filing analysis available with free account →

Recent News

Factual INTS Dilution Snapshot

Intensity Therapeutics, Inc. (INTS) has a DilutionScore of 38/100, rated Medium dilution risk. Score date: October 13, 2026.

This automatically generated snapshot is assembled from stored DilutionWatch data fields and may contain data-source errors or omissions. It is not financial advice, not investment research, and not a recommendation. Do your own research and review the full disclaimer and terms of service.

DilutionScore History — Last 90 Days

INTS's DilutionScore is currently 38/100 (Medium risk), with 3 score changes tracked over 89 days. The score deteriorated from 39/100 (Medium risk).

Period Score Risk Level Duration
Sep 13 – Oct 13, 202638/100MEDIUM31 days
Aug 22 – Sep 12, 202639/100MEDIUM22 days
Aug 14 – Aug 21, 202642/100MEDIUM7 days
Jul 16 – Aug 13, 202636/100MEDIUM29 days

Score recalculated daily from SEC filings and market data. Sign up free for real-time score change alerts.

Share Dilution History

INTS shares outstanding have increased 4.6% from 2.53M (Mar 2026) to 2.65M (May 2026). Each increase represents potential dilution to existing shareholders.

Date Shares Outstanding Public Float Change
May 09, 20262.65M2.47M▲ 6.39%
Apr 17, 20262.54M2.32M▼ 1.60%
Apr 03, 20262.54M2.36M▲ 0.02%
Mar 30, 20262.53M2.36M▲ 5.74%

Share counts sourced from verified regulatory filings. Increases indicate dilution events.

Track INTS Dilution Risk in Real-Time
DilutionWatch monitors SEC filings 24/7 and alerts you the moment INTS files a shelf registration, ATM offering, warrant notice, or convertible note. Free tier available — no credit card required.
Start Tracking INTS — Free
Email alert within minutes of any SEC filing Daily DilutionScore™ recalculation Score history & trend tracking Tracks 8,000+ tickers simultaneously

Related Stocks — MEDIUM Risk

Other MEDIUM dilution risk stocks tracked by DilutionWatch with similar profiles:

→ Biotech / Pharma sector dilution risk overview

Browse all 8,490+ tracked stocks →

📖 Dilution Education
→ Complete Dilution Guide for Retail Investors → Anti-Dilution Provisions Explained → Stock Dilution Red Flags to Watch → Understanding Shelf Registrations
More Research for INTS
INTS FDA Catalyst Timeline & Biotech Grade — BiotechSigns

Part of the Guerilla Finance research network. Cross-reference multiple data sources for better due diligence.